The present invention relates to a method capable of reducing the fat on the liver with the use of resveratrol in humans with Non-Alcoholic Fatty Liver Disease (NAFLD). Resveratrol has been used in the form of micronized formulation, which has strong antioxidant effects and is circulated at the market as a food supplement. Resveratrol (3, 5, 4' - trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem for which effective treatments are required.The study is based on two patient groups. A total of 44 patients (28 men and 16 women) were randomly assigned to groups and were given 50mg resveratrol (n=22) and 200mg (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurement, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study shows the effects of resveratrol on the hepatic enzymes Serum Glutamate Pyruvic Transminase (SGPT) and Gamma- Glutamyl Transpeptidase (g-GT), on the insulin and insulin resistance and on the liver fat. At the end of the study the statistical analysis showed statistical significance reduction on insulin, on the insulin resistance and on the liver fat. These data demonstrate that use of resveratrol improves features of NAFLD, prevents liver damage and that resveratrol can be a new treatment method for NAFLD.
